Allena Pharmaceuticals, Inc. (ALNA)
Stock analysis · NASDAQ · Healthcare · Biotechnology
Allena Pharmaceuticals, Inc. (ALNA) is a publicly traded company in the Healthcare sector. Latest price: $0.08. Trailing PE -0.07. Sign in to Stocks360 for full DCF valuation, fundamentals, technicals, and AI-driven analysis.
Get full analysis → Short-Term Analysis →Earnings
Proprietary Signals
About Allena Pharmaceuticals, Inc.
Allena Pharmaceuticals, Inc. is a biopharmaceutical company focused on the research, development, and market introduction of orally administered enzyme therapies. Operating within the United States, the firm is dedicated to addressing debilitating metabolic and renal conditions, particularly those that are rare and severe. Its primary therapeutic candidate, ALLN-346, is an innovative enzyme designed to break down urate. This treatment is specifically aimed at individuals experiencing hyperuricemia and gout, especially when these conditions coexist with advanced chronic kidney disease. Established in 2011, Allena Pharmaceuticals maintains its corporate headquarters in Newton, Massachusetts.
Valuation
| P/E (TTM) | -0.07× |
|---|---|
| P/S (TTM) | 0.00× |
| P/B | 0.13× |
| P/FCF (TTM) | 0.00× |
| EV / EBITDA | 0.92× |
| EV / Sales | 0.00× |
| Earnings Yield | -1368.13% |
| Free Cash Flow Yield | 0.00% |
Fundamentals
| Enterprise Value | -$29.46M |
|---|---|
| Net Income (TTM) | $0.00 |
| Free Cash Flow (TTM) | -$45.83M |
| Net Debt | -$29.46M |
| Working Capital | $17.33M |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
| Return on Equity | -160.99% |
| Return on Invested Capital | -166.72% |
Peers
Recent News
- No recent news available.
Related
Browse more tickers: sitemap